KiOmed Pharma offers a unique pipeline of medical devices to tackle invalidating OsteoArthritis, Skin Aging and Eye Disorders & Diseases.

KiOmed Pharma accelerates its international growth with CE mark for Kytogen™ Defend, its first aesthetic medicine product

About KiOmed Pharma

Capitalizing on a history of innovation and expertise in exclusive natural chitosan chemistry, KiOmed Pharma, a spinout from KitoZyme, develops a unique pipeline of medical devices that address unmet medical needs in high impact pathologies and major social burdens such as invalidating OsteoArthritis, skin aging and ophthalmology.

Our product KiOmedine-vs-one

Innovative and patented technology

KiOmed Pharma's innovative pipeline is based on a solid building block exclusive technology: KiOmedine® CM-chitosan, a medical-grade natural chitosan derivative with a high purity.

The patented technology KiOmedine® CM-chitosan offers competitive advantages thanks to its immunocompatibility and unique structure. Our scientific team has conducted a large number of safety and efficacy studies to demonstrate the unrivaled properties of the KiOmedine® CM-chitosan technology in various applications :

Excellent lubrication properties
Good scavenging capacity
High ability to protect tissues against oxidative stress

Our technology brings high clinical value to therapeutic solutions and is a technology of choice, suitable for injectable formulations and implantable devices.

KiOmedine® CM-chitosan platform technology

01. Invalidating OsteoArthritis

OsteoArthritis is a degenerative joint disease that affects more than 100 million patients worldwide. It is a debilitating and painful condition that can cause extreme discomfort and limit mobility in those affected. In order to find the most effective treatments, research and development must be undertaken to find new ways of helping those affected by OsteoArthritis find relief and live better lives. Thanks to a unique structure that differs from hyaluronic acid and natural chitosan, our technology KiOmedine® is a component of choice to tackle Osteoarthritis discomfort and other symptoms.

Discover our fluid implant

02. Skin Aging

Thanks to free radical scavenging, KiOmedine®-based dermal fillers provide tunable tissues filling properties with unique skin protection and hydration while stimulating collagen synthesis.

03. Eye Diseases

Thanks to its unique hydrating and lubricating properties, as well as its ability to protect tissues against oxidative stress, KiOmedine® is a component of choice in eyedrops formulations or for more innovative treatments of the posterior segment.

Our injectable medical devices based on CM-chitosan

KioMedine^vsone

KioMedine^vsone is indicated for the symptomatic treatment of knee osteoarthritis. It is given as a single intra-articular injection, administered by a physician. Its structure differs from that of hyaluronic acid, giving it a dual mode of action: improved joint lubrication and protection against oxidative stress.

3 mL pre-filled syringe, ready to use
Single intra-articular injection into the knee
2% CM-chitosan in phosphate-buffered solution, free from animal-derived components
Class III medical device, CE marked (CE 0344)

Kytogen™ Defend

Kytogen™ Defend is a sterile gel for intradermal injection, intended for superficial tissue filling and for improving skin hydration, quality and appearance. It is indicated for adults aged 18 and over with dehydrated skin on the face and décolletage.

Treatment areas: face and décollé
Class III medical device, CE marked (CE 0123)

KYTOGEN™ DEFEND is exclusively distributed and marketed by Sinclair

Beyond treatment, we help people living with knee osteoarthritis maintain and regain their mobility through Arthrose Active, our patient information platform.

Discover the platform

Key facts

Belgianbiotech company
10+ yearsof research and innovation
Pharma grade process
ISO 13485

From years of research to commercial stage

KiOmed Pharma, based in Belgium, is a biotech company that focuses on the development, manufacture and distribution of safe and effective medical devices based on KiOmedine^® CM-Chitosan, our innovative and exclusive animal-free bioresorbable biopolymer.

Through a series of comparative, pre-clinical and clinical studies, KiOmed Pharma repeatedly demonstrated that its exclusive technology KiOmedine® offers unique and sustainable attributes in comparison with competitive products. Our multidisciplinary team experts continually strive to advance innovative solutions to address unmet needs in the treatment of invalidating OsteoArthritis symptoms, dry eye disease and skin aging pathologies.

Discover our team

16 September 2026

KiOmed Pharma accelerates its international growth with CE mark for Kytogen™ Defend, its first aesthetic medicine product

4 September 2026

KiOmed Pharma offers a unique pipeline of medical devices to tackle invalidating OsteoArthritis, Skin Aging and Eye Disorders & Diseases.

KiOmed Pharma accelerates its international growth with CE mark for Kytogen™ Defend, its first aesthetic medicine product

About KiOmed Pharma

Innovative and patented technology